

# ALL WALES MEDICINES STRATEGY GROUP

TUESDAY, 11<sup>TH</sup> DECEMBER 2007 COMMENCING 10.30 AM  
(UNTIL 4.30 PM APPROX)  
AT THE ANGEL HOTEL, ABERGAVENNY, MONMOUTHSHIRE NP7 5EN

## AGENDA

### Enclosure

1. Welcome and introduction
  2. Apologies
  3. Declarations of interest
  4. Chairman's report (verbal update)
  5. Minutes of previous meeting  
- Matters arising 1/AWMSG/1207
  6. **Appraisal 1 - dasatinib (Sprycel<sup>®</sup>)**  
Bristol-Myers Squibb Pharmaceuticals Ltd  
Adults with Philadelphia chromosome positive (PH+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy 2/AWMSG/1207  
Appendices
  7. **Appraisal 2 - dasatinib (Sprycel<sup>®</sup>)**  
Bristol-Myers Squibb Pharmaceuticals Ltd  
Adults with chronic accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate 3/AWMSG/1207  
Appendices
- Note:** *Members will retire to vote in private at the end of the appraisal session. When the meeting re-convenes the Chairman will announce the recommendations of AWMSG. There will be a lunch break from 1.00 pm until 2.00 pm*
8. AWMSG revised Constitution 4/AWMSG/1207
  9. Prescribing Strategy – draft document for comment 5/AWMSG/1207
  10. Report on NHS Industry Forum 6/AWMSG/1207
  11. Report on AWPAG 7/AWMSG/1207
  12. Summary of feedback from members regarding the broadened appraisal process 8/AWMSG/1207

**Date of next AWMSG meeting: Thursday, 14<sup>th</sup> February 2008**  
**Venue – Wales Millennium Stadium**